anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The construction of transgenic animal models for testing potential treatments for Alzheimer's disease are described. The models are characterized by pathology similar to that observed in Alzheimer's disease, based on expression of all three forms of the .beta.-amyloid precursor protein (APP), APP695, APP751, and APP770, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, predicted mutations in the APP gene, and truncated forms of APP that contain the A.beta. region. The APP gene constructs are prepared using the human platelet derived growth factor B(PDGF-B) chain gene promoter, or other promoters able to express A$(b) or mutant forms APP at a high level in transgenic animal brain tissue. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount of APP and .beta.-amyloid peptide, neuropathology, and behavioral alterations.
PROBLEM TO BE SOLVED: To obtain the subject composition obtained from discarded sea urchin shell, excellent in oral absorbing property, having good appearance and taste, hardly containing impurities and useful for preventing and treating hypocalcemia in good yield by baking sea urchin shell. SOLUTION: Sea urchin shell is baked preferably at 500-500 deg.C for 0.5-1.5hr. Concretely, e.g. urchin shell is divided and the meat part is removed and the shell is washed with water and then baked at 1000 deg.C for 1hr in an oven or baked at 800 deg.C for 1hr in a vacuum oven. Thereby, calcium contained in a form of calcium carbonate in sea urchin shell is converted to calcium oxide. The resultant calcium oxide is baked and then, as necessary, can be converted into a readily utilizable form of calcium carbonate, calcium citrate, etc. Furthermore, the composition is usually blended in an amount of 10-50wt.% based on total amount of food, feed, etc.
SystemCHANGE™ focuses on using patients' already established and reliable systems to support medication-taking, rather than focusing on personal effort and "remembering."When applied to medication adherence, the goal is to reduce medication-taking variability and move towards consistently taking medication with a 6-hour window of time (for daily medications like RAAS) and avoid missing medications. SystemCHANGE™ improvement cycles rely on efficient use of performance feedback in order to make decisions about whether system solutions work or if there is a need to select other solutions.
OBJECTIVES: A large-scale nationwide epidemiological survey of lower urinary tract symptoms (LUTS) was conducted via the Internet in 2023 to clarify the current prevalence of LUTS and evaluate its impact on daily life in Japan.
METHODS: The survey was conducted among individuals aged 20-99 years old who had anonymously registered with a Japanese online research company. The survey consisted of 48 questions related to LUTS and daily life.
RESULTS: A total of 6210 participants (3088 females and 3122 males), who were selected by probability sampling based on the composition of the Japanese population (age range: 20-99), were recruited. The overall prevalence of LUTS was 77.9% among the subjects aged ≥20 and 82.5% among those aged ≥40. The prevalence of LUTS differed between the sexes and trends toward significant increases in prevalence with age were seen for almost all LUTS. Furthermore, the prevalence of overactive bladder (OAB) was 11.9% among the subjects aged ≥20 and 13.8% among those aged ≥40. This study also showed that LUTS negatively affected daily life. However, the percentage of subjects who visited a physician to receive treatment for LUTS was low, including for participants with a history of treatment for LUTS, although this increased with age.
CONCLUSION: The prevalence of LUTS, including OAB, increased with age and negatively affected daily life. However, since the percentage of patients who visit a physician to receive treatment for LUTS remains low, further educational activities regarding LUTS are necessary.
Pyridostigmine will be taken as liquid suspension three times a day, scaling up from 20mg (1.67mL) to 60mg (5mL) (180mg/day). Placebo will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL.
The present invention provides substances suitable for use as vaccines for the prevention of EBV infection and EBV-associated disorders and methods for administering them. The vaccines are directed against HERV-K18 env (SEQ ID:1) and most preferably comprise antigens obtained from HERV-K18 env. Preferred antigens include SEQ ID:2, SEQ ID:3 and SEQ ID:4. Most preferably, the SAg T  cell stimulatory activity of the HERV-K18 env is diminished or eliminated. In another embodiment, the vaccine contains a nucleic acid encoding HERV-K18 env or an immunogenic fragment thereof. The present invention also provides methods for treating EBV infection and EBV-associated disorders.
Combination arm. NIZ985 and Spartalizumab combination is administered starting at Cycle 1 Day 1 in dose escalation. NIZ985 and tislelizumab combination is administered starting at Cycle 1 Day 1 in dose expansion.
A method of delivering a contrast enhancing fluid to a patient using an injector system, including: determining at least one patient transfer function for the patient based upon data specific to the patient, the at least one patient transfer function providing a time enhancement output for a given input; determining a desired time enhancement output; using the at least one patient transfer function to determine an injection procedure input; and controlling the injector system at least in part on the basis of the determined injection procedure input. The injection procedure input can determined considering at least one operational limitation or constraint of the injector system. A method of modeling propagation of a pharmaceutical fluid in a patient, includes: collecting data corresponding to a time response curve resulting from injection of the fluid; and determining at least one mathematical model describing the data. The mathematical model can, for example, be a model which is not determined by a continuous or a discrete-time Fourier deconvolution of the data. A method of controlling injection of a pharmaceutical fluid into a patient using an injector in a medical procedure, includes: collecting data corresponding to a patient response curve resulting from injection of the fluid; determining at least one mathematical model describing the data; and controlling the injector during the medical procedure to control injection of the fluid into the patient to create patient response at least in part on the basis of the mathematical model. A method of controlling injection of a contrast medium into a patient using an injector in a medical imaging procedure using an imaging scanner, includes: determining at least one mathematical model to predict a time enhancement response resulting from injection of the contrast medium; determining an injection protocol to approximate a predetermined time enhancement response in the patient by determining a constrained input solution to the mathematical model; and using the injection protocol to control the injector during the medical imaging procedure to control injection of the contrast medium into the patient to create an image of a region of interest.
PURPOSE: Acute allergic reactions may occur in susceptible individuals following exposure to various allergens. Obesity is linked to allergic reactions, and weight loss from bariatric surgery may attenuate the severity of certain conditions such as airway hyperresponsiveness in asthma. This retrospective observational study investigates associations between prior bariatric surgery and lower risk for life-threatening conditions in patients hospitalized with acute allergic reactions and anaphylaxis.
MATERIALS AND METHODS: Adults ≥ 18 years old diagnosed with morbid obesity and admitted to US hospitals with acute allergic reactions/anaphylaxis were included. All data were extracted from the US Nationwide Inpatient Sample (NIS) database 2005-2018. Patients without information on in-hospital mortality, discharge destination, hospital costs, and length of stay (LOS) were excluded. Patients were divided into two groups based on prior bariatric surgery or not. All diagnoses were verified through ICD-9 and ICD-10 codes. Between-group differences and associations between variables were evaluated using logistic regression analysis.
RESULTS: After matching, patients with prior bariatric surgery had significantly lower proportions of any life-threatening morbidity (37.2% vs. 47.4%), respiratory distress or failure (11.2% vs. 17.0%), pneumonia or severe infection (7.4% vs. 10.2%), sepsis/septic shock (15.2% vs. 20.9%), intubation and mechanical ventilation (11.2% vs. 14.6%), prolonged LOS (10.3% vs. 20.6%) and unfavorable discharge (6.9% vs. 12.5%) than those without prior bariatric surgery.
CONCLUSION: Prior bariatric surgery predicts a lower risk of life-threatening morbidity and prolonged LOS among adults hospitalized for acute allergic reaction and anaphylaxis. Future prospective studies are warranted to confirm the present findings and reveal underlying mechanisms.
An event at a location is identified. An event risk of the event can be calculated based on risk characteristics of both the location of the event (“location risk characteristics”) and the event itself (“personnel risk characteristics”). Location risk characteristics can include a visitor history of the location. Personnel risk characteristics can be based on attendees of the event, such as a number of attendees. The overall event risk, once calculated, can be compared to a threshold. Depending on the comparison, a risk mitigation policy can be implemented.
The invention relates to a chimeric antigen receptor (CAR) having a DNA-sequence. The fields of application are medicine and the pharmaceutical industry. The invention relates to a novel chimeric antigen receptor (CAR). The receptor detects the carcinoembryonic antigen (CEA) on tumor cells. The chimeric receptor consists of a DNA sequence produced from a CEA-specific antibody, which is connected to the DNA sequence of the zeta-chain of the T cell receptor via a linker sequence. If the DNA sequence of said chimeric antigen receptor (CAR) is inserted into a plasmide or a vector and if said plasmid or vector is brought into immune cells by gene transfer, said immune cells can detect the antigen on cancer cells and lyse said cancer cells. The invention makes available an agent for specific therapy of malignant diseases.
OBJECTIVE: This study aims to perform a prenatal genetic diagnosis of a high-risk fetus with trisomy 7 identified by noninvasive prenatal testing (NIPT) and to evaluate the efficacy of different genetic testing techniques for prenatal diagnosis of trisomy mosaicism.
METHODS: For prenatal diagnosis of a pregnant woman with a high risk of trisomy 7 suggested by NIPT, karyotyping and chromosomal microarray analysis (CMA) were performed on an amniotic fluid sample. Low-depth whole-genome copy number variation sequencing (CNV-seq) and fluorescence in situ hybridization (FISH) were used to clarify the results further. In addition, methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) was performed to analyze the possibility of uniparental disomy(UPD).
RESULTS: Amniotic fluid karyotype analysis revealed a 46, XX result. Approximately 20% mosaic trisomy 7 was detected according to the CMA result. About 16% and 4% of mosaicism was detected by CNV-seq and FISH, respectively. MS-MLPA showed no methylation abnormalities. The fetal ultrasound did not show any detectable abnormalities except for mild intrauterine growth retardation seen at 39 weeks of gestation. After receiving genetic counseling, the expectant mother decided to continue the pregnancy, and follow-up within three months of delivery was normal.
CONCLUSION: In high-risk NIPT diagnosis, a combination of cytogenetic and molecular genetic techniques proves fruitful in detecting low-level mosaicism. Furthermore, the exclusion of UPD on chromosome 7 remains crucial when NIPT indicates a positive prenatal diagnosis of trisomy 7.
Neupogen®(Filgrastim) 10 ㎍/kg or Leucostim®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 10 ㎍/kg or Neupogen®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
The insulin-resistant state of type 2 diabetes mellitus (T2DM) is largely mediated by inflammatory pathways affecting skeletal muscle which is the primary site of whole body insulin resistance. Nuclear factor kappa B (NFkappaB) regulates pro-inflammatory cytokines which ultimately impair skeletal muscle insulin signaling and fatty acid oxidation; its activity reflects overall inflammatory tone in skeletal muscle. Recent human studies confirm that NFkappaB is elevated in the skeletal muscle of T2DM human subjects. Furthermore, the same inflammatory processes and signaling impairments contribute to worsening endothelial dysfunction, which is an independent predictor for future cardiovascular events in T2DM. In addition, these SGLT-2 Inhibitors reduce body weight, visceral adiposity, systolic and diastolic blood pressure, microalbuminuria, and oxidative stress. However, there are no studies examining the effects of SGLT-2 inhibitor therapy on NFkappaB and other inflammatory mediators in humans with T2DM. Moreover, no studies have examined the effect of SGLT-2 inhibitor therapy on endothelial function in this population. In the present study the investigators will assess whether dapagliflozin treatment for 12 weeks reduces monocyte inflammation and improves endothelial dysfunction in patients with type 2 diabetes on metformin monotherapy.
Long-course chemoradiation plus PD-1 inhibition with no PD-1 inhibition. TME surgery is scheduled in 6\~12 weeks after completion of radiation.
FIELD: chemistry. ^ SUBSTANCE: invention relates to a method of obtaining 10-deacetylbaccatine III with purity of over 99%, which does not contain 10-deacetyl-2-debenzoyl-2-pentenoylbaccatine III. The disclosed method includes: a) treating crude 10-deacetylbaccatine III with an activated derivative of trichloroacetic acid; b) carrying out chromatography on silica gel and elution of 7,10-bis-trichloroacetyl-10-deacetylbaccatine III with dichloromethane or a dichloromethane/ethylacetate mixture; and c) treatment of 10-deacetyl-7,10-bis-trichloroacetylbaccatine III with an alkali followed by crystallisation. The invention also relates to production of paclitaxel, which involves production of 10-deacetylbaccatine III using the disclosed method and its subsequent conversion to N-debenzoylpaclitaxel with its subsequent benzoylation. ^ EFFECT: convenient semi-synthesis of anti-tumour agents with a taxane backbone, which enables to avoid laborious methods of removing corresponding 2-debenzoyl-2-pentenoyl analogues. ^ 7 cl, 1 tbl, 3 ex
Early diagnosis of HCC is the most important factor in improving the prognosis of the disease. A surveillance test for early diagnosis of HCC in Korea is to perform alfa fetoprotein (AFP) and abdominal sonography every 6-months in high-risk groups. However, the detection rate of HCC using AFP and abdominal sonography is very low. There are several reports that the combination of the multiple biomarker tests including AFP, AFP L3, and PIVKA-II increased the early HCC detection only one test. Therefore, in the surveillance test for HCC, the combination of three tests with sonography would be helpful in the early diagnosis of HCC. However, there was few prospective large-scale studies about this issue.

Compared with abdominal sonography, contrast-enhanced CT or MRI is more useful in finding intrahepatic lesions of liver cirrhosis. However, there is no evidence data on combining sono/CT and biomarkers could improve the diagnosis for early HCC. Thus, it is essential to verify this prospectively in the real clinical practices to make recommendations based on a high level of evidence in the future. The investigators are conducting a prospective study which examines three biomarker tests and sonography every six months and contrast-enhanced CT annually for HCC surveillance in patients with cirrhosis.
The invention discloses application of a staphylokinase derivative in preparation of a blood lipid-lowering drug and belongs to the field of biomedicines. The amino acid sequence of the staphylokinase derivative is an amino acid sequence shown in the claim 1 in a Chinese patent document (CN1850976). The staphylokinase derivative disclosed by the invention acts on an ApoE-/-mouse and quail by way of intravenous injection so as to remarkably reduce total plasma cholesterol (TG), triglyceride (TC) and level of low density lipoprotein (LDL-c); and in an equivalent time, the blood-lipid-lowering effect and the curative effect of the derivative are superior to those of statins. Within 2 weeks of intravenous injection, an obvious liquid-lowering effect can be displayed, and moreover, the inflammation level of the body can be further obviously inhibited and the oxidative stress state is improved. An SAK-HV protein engineering bacterium is prepared by virtue of a bioengineering method. Through process optimization, the expression quantity can reach 45%; and through fermentation and purification, the protein purity can reach 95% or more.
NEW MATERIAL:A 1-substituted-amino-4-substituted 2-butene compound shown by the formula I (R is lower alkyl, or phenyl) and its acid addition salt. EXAMPLE:Trans-1-(2,6-dichlorophenyl-2-imidazolin-2-yl)amino-4-methoxy- 2-butene. USE:A drug acting on the circulatory organs. Useful as a preventive and remedy especially for cardiac incompetence, diseases of coronary artery, or arrhythmia of heart, an anti-inflammatory agent, or an analgesic. PREPARATION:A 1-halo-2-butene compound shown by the formula II (Hal is halogen such as Cl, Br, or I) is reacted with 2-(2,6-dichlorophenyl) aminoimidazoline (2) in a solvent such as ethanol, etc. in the presence or absence of a dehydrohalogenating agent such as an alkali metal carbonate, etc. at 20-50 deg.C for 3-50hr, to give a compound shown by the formula I .
The invention discloses a configuration method, a device, a medium and equipment of blood pressure message data, comprising the following steps: firstly, analyzing the blood pressure message data received in real time, and extracting a first standard name, a first blood pressure parameter item, a blood pressure parameter value and equipment information. And then, finding out the associated user through the equipment information, acquiring all sign parameter configurations under the department to which the associated user belongs, and analyzing a second label and a second blood pressure parameter item of each configuration. And matching the first standard name and the blood pressure parameter item with the second standard name and the parameter item of each feature parameter configuration to obtain a configuration identifier meeting the matching requirement. And finally, the first label, the first blood pressure parameter item, the blood pressure parameter value, the user identification and the matched configuration identification are used as a record to be stored in a sign table. The method simplifies the process of acquiring the information by the user, does not need complicated operation, and is convenient for information comparison. The recorded configuration identifier is helpful for the user to accurately interpret and utilize the blood pressure data transmitted by the monitoring device when the user inquires the data later.
This study aims to explore the roles of phenylacetyl glutamine (PAGln) on myocardial infarction (MI) pathogenesis. Here, using targeted metabolomics analysis, it was found that the plasma metabolite PAGln was upregulated in coronary artery disease (CAD) patients and MI mice and could be an independent risk factor for CAD. In vivo and in vitro functional experiments revealed that PAGln pretreatment enhanced MI-induced myocardial injury and cardiac fibrosis, as evident by the increased infarct size, cardiomyocyte death, and the upregulated expression of cardiac fibrosis markers (Col1a1 and α-SMA). Combined with RNA-sequencing analysis and G protein-coupled receptor (GPCR) inhibitor, we found that the GPCR signaling activation is essential for PAGln-mediated effects on cardiomyocyte death. Furthermore, drug affinity responsive target stability and cellular thermal shift assay demonstrated that PAGln could interact with β1-adrenergic receptor (AR). Moreover, β1-AR blocker treatment indeed extended the cardiac remodeling after PAGln-enhanced MI. These results suggest that PAGln might be a potential therapeutic target for extending the cardiac remodeling window in MI patients that signals via β1-AR.
MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is a palatable lemon-vanilla flavored water-soluble iodinated radiopaque contrast medium for oral or rectal administration only. Each mL contains 660 mg diatrizoate meglumine and 100 mg diatrizoate sodium; pH has been adjusted to 6.0 to 7.6 with sodium hydroxide. Each mL contains approximately 4.8 mg (0.21 mEq) sodium and 367 mg organically bound iodine. MD-Gastroview does not contain the wetting agent polysorbate 80. 

The inactive ingredients are: Edetate Disodium Dihydrate, Lemon-Vanilla Flavor, Sodium Citrate, Sodium Hydroxide, Sodium Saccharin, Water for Injection. Air in the container is displaced with nitrogen. 

Diatrizoate meglumine is designated chemically as 1-deoxy-1-(methylamino)-D-glucitol 3,5-diacetamido-2,4,6-triiodobenzoate (salt); diatrizoate sodium is monosodium 3,5-diacetamido-2,4,6-triiodobenzoate. The two salts have the following structural formulae:
To understand the effects of non-weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based upper arm ergometry interventions may include arm crank training (upper arm ergometry) in while seated in the wheelchair 5 days a week for a total of 80, 1-hour sessions.
The natural course (control) group consisted of 32 eyes of 16 RP patients who received no treatment and were regularly followed until the 36th month. This group comprised patients who did not accept any treatment and/or were in good condition at baseline.
Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15, and paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
A three-week wash-out period. All participants will attend 6 measurement sessions across the 3-week period but will not complete any swallowing exercises.